Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial.

However, all these variables were highly significant improvement with empagliflozin therapy, which allows us to determine the ability of empagliflozin to reduce LV filling pressure in diabetic patients with HFpEF.

also in 132,142 other papers

In this study, empagliflozin treatment was associated with a significant reduction in the fibrotic biomarker sST2 and a clear trend towards a reduction in the inflammatory biomarker hsCRP, both of which correlated well with the reduction in NT-proBNP achieved.

also in 19,460 other papers